Five of these patients acquired mutations in components or regulators of the RAS signaling pathway (KRAS, NRAS, PTPN1, BRAF and FLT3), suggesting that activation of RAS pathway is probably involved in the evolution of CMML in some patients. This evidence concerns the gene FLT3 and chronic myelomonocytic leukemia.